YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* FibroGen (KYNB [https://seekingalpha.com/symbol/KYNB]) is scheduled to announce Q2 earnings results on Thursday, August 13th, after market close. * The consensus EPS estimate is -$3.18, [https://seekingalpha.com/symbol/KYNB/earnings/esti…
Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-re…
NovoCure (NVCR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.36 per share a year ago. These figures are adjusted for non-recurring items. This quarte…
Earnings Call Insights: Kyntra Bio (KYNB) Q1 2026 MANAGEMENT VIEW * CEO Thane Wettig said the quarter’s focus remained on “consistent progress we have made across our portfolio,” highlighting “FG-3246, our potential first-in-class antibody…
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $1.24 per share a year ago. These figures are adjusted for non-recurring ite…
* FibroGen (KYNB [https://seekingalpha.com/symbol/KYNB]) is scheduled to announce Q4 earnings results on Monday, March 16th, after market close. The consensus EPS Estimate is -$3.88 [https://seekingalpha.com/symbol/KYNB/earnings/estimates]…
FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic prog…